



sarah.aiosa@gmail.com; m: 973-943-7192; West Orange, New Jersey
www.linkedin.com/in/sarah-m-aiosa-mph-a0574912

Sarah Aiosa is a bilingual Senior Executive, Change Catalyst and Board Member with a Master's in Public Health from The Johns Hopkins University. She is a visionary leader with extensive experience in the Life Sciences across International Commercial Operations, Corporate Strategy, Mergers and Acquisitions, as well as Foreign Affairs/Public Policy. Sarah possesses a proven track record of driving broad transformation and profitable growth, yet with diligent enterprise risk and crisis management. She is known for building and inspiring a highly engaged workforce and cultivating a strong corporate culture.

Board Appointments:

In January 2024, Sarah was appointed to the Board of the New Jersey Performing Arts Center, the anchor Nonprofit cultural institution for the state of New Jersey that focuses on impactful arts and community programming. Since 2022, Sarah has served on the Board of the Council of the Americas (COA), founded by David Rockefeller, where she is on the Membership Committee. The COA is a premier international business organization whose members share a commitment to economic and social development, trade, the rule of law, and democracy throughout the Western Hemisphere. She holds an elected seat as the 2024-2025 Chair of the Board of Directors for the U.S.-Colombia Business Council, founded by the U.S. Chamber of Commerce. She recently completed service as Chair of the Board of FIFARMA, the Latin American Federation of the Pharmaceutical Industry from May 2023 through December 2024.

Current Operational Executive Leadership:

Since February 2022, Sarah has held the role of President, Latin America for Merck & Co., a Fortune 500 Multinational Pharmaceutical Company, where she leads the Human Health business with a P&L of +\$2.3 Billion (B) in Sales, encompassing a vast portfolio of medicines and vaccines with oversight of ~5,000 employees in more than 30 countries. Sarah is the first woman President in the company's history to lead Latin America. She has delivered exceptional double-digit financial results year over year, as follows:

- 2022: ~\$1.9B in topline revenue, growing 18% vs. 2021
- 2023: ~\$2.3B in topline revenue, growing 24% vs. 2022
- 2024: Q3 Year to Date (YTD): ~\$2B in topline revenue, growing 15% vs. Q3 YTD 2023

Notably, Latin America is now *the fastest growing region for Merck*, with the Brazil and Mexico affiliates entering in the company's top 10 ranking of ex-US international markets by revenue.

Formerly, Sarah was CEO of the Merck affiliate in Sweden where she managed a ~\$200M P&L and the company was certified among the Best Places to Work. Sarah has an extensive background working in strategic and operational roles at several multinationals, including Novartis, Sanofi, and Eli Lilly. She is an Executive Member of the Latino Corporate Directors Association (LCDA) and obtained her Board Ready Certification for Excellence in Board Governance by LCDA, KPMG and University of California Law San Francisco in 2023.